ArticlePharmacological reports : PR2026
Cannabidiol (CBD) modulates the serotonin-kynurenine metabolic balance in the brain of morphine-tolerant neuropathic rats.
Article in Pharmacological reports : PR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeuropathic pain (NP) is a chronic and debilitating condition that remains difficult to treat, with opioids like morphine often leading to tolerance and reduced efficacy over time. Cannabidiol (CBD) has emerged as a potential therapeutic for NP even in morphine tolerance conditions; however, its effects on nociceptive modulation and neurotransmitter metabolism in morphine-tolerant NP models remain poorly understood. This study investigated the impact of CBD on mechanical hypersensitivity and on tryptophan (TRP) metabolism via the serotonin (5-HT) and kynurenine (KYN) pathways and dopamine (DA) in Wistar rats with NP and morphine tolerance.
methodsNP was induced using the spared nerve injury (SNI) model. Animals received morphine (5 mg/kg, subcutaneous (sc), twice daily) for 7 days to induce tolerance. On Day 8, rats were treated with CBD (20 mg/kg, ip) or vehicle. Mechanical hypersensitivity was assessed, and TRP metabolism and DA were evaluated in different brain regions and serum.
resultsRepeated morphine induced tolerance to its analgesic effects. CBD significantly reduced mechanical hypersensitivity in non-tolerant rats, with a modest effect in morphine-tolerant animals. In tolerant rats, CBD increased 5-hydroxytryptophan (5-HTP)/TRP ratio in hippocampus and midbrain and reduced KYN levels in the hippocampus, indicating a shift toward 5-HT synthesis. CBD also lowered DA and the 5-HTP/TRP ratio in the brainstem, and decreased serum TRP and 5-HT.
conclusionsCBD treatment in NP morphine-tolerant rats exerted a modest effect on mechanical hypersensitivity and was associated with a partial counteraction of metabolic dysregulation by reducing KYN production and shifting TRP metabolism toward 5-HT synthesis (increased 5-HTP/TRP ratio). These findings suggest that CBD modulates 5-HT tone through region-specific mechanisms associated with the development of morphine tolerance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.